Primary esophageal non-Hodgkin's lymphoma. 1992

T Tsukada, and T Ohno, and H Kihira, and M Taniguchi, and T Takahashi, and S Arima, and H Yamada, and Y Akasaka, and H Yokoi, and K Kita
Second Department of Internal Medicine, Mie University School of Medicine, Tsu, Japan.

A 77-year-old woman with primary esophageal non-Hodgkin's lymphoma in clinical stage IEA (Ann Arbor Classification) developed pain and difficulty in swallowing. An upper gastrointestinal examination revealed a submucosal tumor from the upper to the middle portion of the esophagus. Histopathological examination at endoscopic biopsy with endoscopic partial incision showed non-Hodgkin's lymphoma (diffuse type--large cell). Immunohistological examination of tumor cells disclosed LCA (+), CD3(DAKO) (+), MT1 (+), UCHL1 (+), MB1 (+), MxPanB (-) and EMA (-) reactivity and showed T cell lymphoma. The clinical stage was determined to be IEA after further work-up. Improvement of swallowing difficulty and esophageal findings on upper gastrointestinal series were noted after modified CHOP therapy and radiotherapy (total 50 Gy).

UI MeSH Term Description Entries
D011241 Prednisone A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver. Dehydrocortisone,delta-Cortisone,Apo-Prednisone,Cortan,Cortancyl,Cutason,Dacortin,Decortin,Decortisyl,Deltasone,Encorton,Encortone,Enkortolon,Kortancyl,Liquid Pred,Meticorten,Orasone,Panafcort,Panasol,Predni Tablinen,Prednidib,Predniment,Prednison Acsis,Prednison Galen,Prednison Hexal,Pronisone,Rectodelt,Sone,Sterapred,Ultracorten,Winpred,Acsis, Prednison
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D004938 Esophageal Neoplasms Tumors or cancer of the ESOPHAGUS. Cancer of Esophagus,Esophageal Cancer,Cancer of the Esophagus,Esophagus Cancer,Esophagus Neoplasm,Neoplasms, Esophageal,Cancer, Esophageal,Cancer, Esophagus,Cancers, Esophageal,Cancers, Esophagus,Esophageal Cancers,Esophageal Neoplasm,Esophagus Cancers,Esophagus Neoplasms,Neoplasm, Esophageal,Neoplasm, Esophagus,Neoplasms, Esophagus
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy
D014750 Vincristine An antitumor alkaloid isolated from VINCA ROSEA. (Merck, 11th ed.) Leurocristine,Citomid,Farmistin,Oncovin,Oncovine,Onkocristin,Vincasar,Vincasar PFS,Vincristin Bristol,Vincristin medac,Vincristine Sulfate,Vincrisul,Vintec,cellcristin,PFS, Vincasar,Sulfate, Vincristine

Related Publications

T Tsukada, and T Ohno, and H Kihira, and M Taniguchi, and T Takahashi, and S Arima, and H Yamada, and Y Akasaka, and H Yokoi, and K Kita
January 2005, Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology,
T Tsukada, and T Ohno, and H Kihira, and M Taniguchi, and T Takahashi, and S Arima, and H Yamada, and Y Akasaka, and H Yokoi, and K Kita
August 1984, The American journal of medicine,
T Tsukada, and T Ohno, and H Kihira, and M Taniguchi, and T Takahashi, and S Arima, and H Yamada, and Y Akasaka, and H Yokoi, and K Kita
May 1985, Journal de radiologie,
T Tsukada, and T Ohno, and H Kihira, and M Taniguchi, and T Takahashi, and S Arima, and H Yamada, and Y Akasaka, and H Yokoi, and K Kita
September 2004, Japanese journal of clinical oncology,
T Tsukada, and T Ohno, and H Kihira, and M Taniguchi, and T Takahashi, and S Arima, and H Yamada, and Y Akasaka, and H Yokoi, and K Kita
June 1999, Sangre,
T Tsukada, and T Ohno, and H Kihira, and M Taniguchi, and T Takahashi, and S Arima, and H Yamada, and Y Akasaka, and H Yokoi, and K Kita
May 1994, Annals of surgical oncology,
T Tsukada, and T Ohno, and H Kihira, and M Taniguchi, and T Takahashi, and S Arima, and H Yamada, and Y Akasaka, and H Yokoi, and K Kita
February 1995, Southern medical journal,
T Tsukada, and T Ohno, and H Kihira, and M Taniguchi, and T Takahashi, and S Arima, and H Yamada, and Y Akasaka, and H Yokoi, and K Kita
August 1998, Clinical radiology,
T Tsukada, and T Ohno, and H Kihira, and M Taniguchi, and T Takahashi, and S Arima, and H Yamada, and Y Akasaka, and H Yokoi, and K Kita
April 1998, [Rinsho ketsueki] The Japanese journal of clinical hematology,
T Tsukada, and T Ohno, and H Kihira, and M Taniguchi, and T Takahashi, and S Arima, and H Yamada, and Y Akasaka, and H Yokoi, and K Kita
January 2011, European journal of gynaecological oncology,
Copied contents to your clipboard!